Triple-negative breast cancer (TNBC), lacking the expression of ER, PR, and ErbB2/HER2, presents the poorest prognosis among breast cancer subtypes, with chemotherapy as standard treatment. This evidence concerns the gene ESR1 and breast carcinoma.